1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2020, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 17, 134, 194, 1, 18, 159, 35 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 12, 9, 1, 10 and 4 molecules, respectively.
Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Gastric Cancer - Overview
- Gastric Cancer - Therapeutics Development
- Gastric Cancer - Therapeutics Assessment
- Gastric Cancer - Companies Involved in Therapeutics Development
- Gastric Cancer - Drug Profiles
- Gastric Cancer - Dormant Projects
- Gastric Cancer - Discontinued Products
- Gastric Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Gastric Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Gastric Cancer - Pipeline by 3SBio Inc, H2 2020
- Gastric Cancer - Pipeline by AbbVie Inc, H2 2020
- Gastric Cancer - Pipeline by AbClon Inc, H2 2020
- Gastric Cancer - Pipeline by Abion Inc, H2 2020
- Gastric Cancer - Pipeline by ABL Bio Inc, H2 2020
- Gastric Cancer - Pipeline by Abpro Corp, H2 2020
- Gastric Cancer - Pipeline by Acepodia Biotech Inc, H2 2020
- Gastric Cancer - Pipeline by Acrotech Biopharma LLC, H2 2020
- Gastric Cancer - Pipeline by AD Pharmaceuticals Co Ltd, H2 2020
- Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2020
- Gastric Cancer - Pipeline by ADC Therapeutics SA, H2 2020
- Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
- Gastric Cancer - Pipeline by Affimed GmbH, H2 2020
- Gastric Cancer - Pipeline by AffyImmune Therapeutics Inc, H2 2020
- Gastric Cancer - Pipeline by Agenus Inc, H2 2020
- Gastric Cancer - Pipeline by AIMM Therapeutics BV, H2 2020
- Gastric Cancer - Pipeline by Akeso Inc, H2 2020
- Gastric Cancer - Pipeline by Alkermes Plc, H2 2020
- Gastric Cancer - Pipeline by Alligator Bioscience AB, H2 2020
List of Figures
- Number of Products under Development for Gastric Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AbbVie Inc
- AbClon Inc
- Abion Inc
- ABL Bio Inc
- Abpro Corp
- Acepodia Biotech Inc
- Acrotech Biopharma LLC
- AD Pharmaceuticals Co Ltd
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- Affimed GmbH
- AffyImmune Therapeutics Inc
- Arog Pharmaceuticals Inc
- Biomunex Pharmaceuticals
- BioNTech SE
- Biosion Inc
- Biotecnol Ltd
- BJ Bioscience Inc
- Bliss Biopharmaceutical (Hangzhou) Co Ltd
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Bolt Biotherapeutics Inc
- Bristol-Myers Squibb Co
- Byondis BV
- CalyGene Biotechnology Inc
- Camel-IDS NV
- Cancer Prevention Pharmaceuticals Inc
- Cannabics Pharmaceuticals Inc
- CARsgen Therapeutics Ltd
- CAS-Lamvac Biotech Co Ltd
- Catalent Inc
- Celldex Therapeutics Inc
- CureLab Oncology Inc
- CureMeta LLC
- Cynvec LLC
- Cytocom Inc
- Cytodyn Inc
- CytoMed Therapeutics Pte Ltd
- CytomX Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Delta-Fly Pharma Inc
- DiNonA Inc
- DM Bio Ltd
- Dr. Reddy's Laboratories Ltd
- Dragonfly Therapeutics Inc
- Eddingpharm Inc
- eFFECTOR Therapeutics Inc
- Genexine Inc
- Genmab AS
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GLG Pharma SA
- GlycoNex Inc
- Glycotope GmbH
- Good T Cells Inc
- Gossamer Bio Inc
- Green Cross LabCell Corp
- Grid Therapeutics LLC
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- HaimBio Ltd
- Hangzhou DAC Biotech Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Jiuzhitang Co Ltd
- Johnson & Johnson
- Jounce Therapeutics Inc
- JW Pharmaceutical Corp
- Karyopharm Therapeutics Inc
- KLUS Pharma Inc
- Komipharm International Co Ltd
- Konruns Pharmaceutical Co Ltd
- Kringle Pharma Inc
- Kupffer Biotherapeutics Inc
- Kymab Ltd
- Kyowa Kirin Co Ltd
- LATITUDE Pharmaceuticals Inc
- Leap Therapeutics Inc
- Legend Biotech Corp
- Ocellaris Pharma Inc
- Ona Therapeutics SL
- OncoImmune Inc
- Oncolys BioPharma Inc
- OncoSynergy Inc
- OncoTherapy Science Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Onxeo SA
- Opsona Therapeutics Ltd
- Orano Med LLC
- Origincell Technology Group Co Ltd
- Oxford BioTherapeutics Ltd
- Patrys Ltd
- Peptron Inc
- PersonGen Biomedicine Suzhou Co Ltd
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharma Mar SA
- Pharmapraxis
- Philogen SpA
- Phosplatin Therapeutics LLC
- Pieris Pharmaceuticals Inc
- Plus Therapeutics Inc
- PNB Vesper Life Science Pvt Ltd
- Prescient Therapeutics Ltd
- Prestige BioPharma Pte Ltd
- ProLynx LLC
- Protheragen Inc
- Puma Biotechnology Inc
- QED Therapeutics Inc
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Quadriga BioSciences Inc
- QureBio Ltd
- Rakuten Medical Inc
- RAPT Therapeutics Inc
- RaQualia Pharma Inc
- Redx Pharma Plc
- Relay Therapeutics Inc
- RemeGen Ltd
- Rhizen Pharmaceuticals SA
- RUS Pharmtech
- Samumed LLC
- Samyang Holdings Corp
- Sanofi
- Scancell Holdings Plc
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Seven and Eight Biopharmaceuticals Corp
- Shandong Golden Brick Biotechnology Co Ltd
- Shanghai Biomed-Union Biotechnology Co Ltd
- Shanghai Bioray Laboratory Inc
- Shanghai GeneChem Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Keqi Pharmaceutical Technology Co Ltd
- Shanghai Miracogen Inc
- Shanghai PerHum Therapeutics Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shaperon Inc
- Shenyang Dongxing Pharmaceutical Co Ltd
- Shenzhen BinDeBio Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shenzhen Fapon Biopharma Inc
- Shenzhen Hornetcorn Bio-technology Company Ltd
- Shenzhen NeoCura Biotechnology Corp
- Shijiazhuang No. 4 Pharmaceutical Co Ltd
- Shijiazhuang Sagacity New Drug Development Co Ltd
- Shionogi & Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Silicon Therapeutics LLC
- Sillajen Biotherapeutics
- Sino Biopharmaceutical Ltd
- SN BioScience
- Sorrento Therapeutics Inc
- Sotio AS
- Sparx Therapeutics Inc
- Spring Bank Pharmaceuticals Inc
- Stcube Inc
- Stemirna Therapeutics Inc
- Sumitomo Dainippon Pharma Co Ltd
- Sunstem Biotechnology Co Ltd
- Suntec Medical (Taiwan) Inc
- Suzhou Sinovent Pharmaceuticals Co Ltd
- Suzhou Zanrong Pharmaceutical Technology Co Ltd
- SynCore Biotechnology Co Ltd
- Systimmune Inc
- T-Cure Bioscience Inc
- TAE Life Sciences LLC
- Taiho Oncology Inc
- Taiho Pharmaceutical Co Ltd
- Takis Srl
- Tarveda Therapeutics Inc
- Tasly Pharmaceutical Group Co Ltd
- Tempest Therapeutics Inc
- Tessa Therapeutics Ltd
- Themis Bioscience GmbH
- Tonix Pharmaceuticals Holding Corp
- Toray Industries Inc
- TOT Biopharm Co Ltd
- Transcenta Holding Ltd
- Transcode Therapeutics Inc
- Treos Bio Ltd
- Trio Medicines Ltd
- Triumvira Immunologics Inc
- Turning Point Therapeutics Inc
- Turnstone Biologics Inc
- Tvardi Therapeutics Inc
- Tyg Oncology Ltd
- Ube Industries Ltd
- United BioPharma Inc
- Vaxon Biotech
- Vedanta Biosciences Inc
- Venus Remedies Ltd
- Viracta Therapeutics Inc
- Viral Gene Inc
- Viralytics Pty Ltd
- VM Discovery Inc
- WellMarker Bio Co Ltd
- Wellmarker Bio Co Ltd
- Wuhan YZY Biopharma Co Ltd
- Xcovery Holding Co LLC
- Xencor Inc
- Xiangxue Life Sciences
- XuanZhu Pharma Co Ltd
- Zai Lab Ltd
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang Jianfeng Group Company Ltd
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
- Zymeworks Inc
